Top Markets
Coin of the day
Windlas Biotech Limited Windlas Biotech Limited

Windlas Biotech Limited

WINDLAS
株式のランク #17129
Windlas Biotech Limited functions as a comprehensive contract development and... Windlas Biotech Limited functions as a comprehensive contract development and manufacturing organization (CDMO). Its CDMO offerings span the full product lifecycle, encompassing initial discovery, subsequent development, licensing, and large-scale commercial production of various generic pharmaceutical and nutraceutical items. Through these services, it assists clients in bringing both established and innovative pharmaceutical and nutraceutical products to market, which are then sold under the clients' proprietary brand names. Beyond its CDMO segment, Windlas Biotech also develops and manufactures its own portfolio of domestic trade generics and over-the-counter (OTC) brands, catering to the nutritional, ayurvedic, wellness, and personal care sectors. These in-house products reach consumers via a dual distribution approach: traditional offline channels like distributors, stockists, retail pharmacies, and institutional tenders, alongside a robust online presence through various e-commerce platforms. The company's international reach extends through exports, primarily to markets such as Vietnam, Myanmar, Sri Lanka, Thailand, the Philippines, Cambodia, Fiji, Trinidad & Tobago, and South Africa. Established in 2001, Windlas Biotech is headquartered in Gurugram, India.
株価
$12.15
時価総額
$257.09M
変化(1日)
10.00%
変化(1年)
9.99%
IN
取引 Windlas Biotech Limited (WINDLAS)

カテゴリー

Windlas Biotech Limited(WINDLAS)の営業利益率
2026 時点の営業利益率 TTM: 0.00%
Windlas Biotech Limited の最新の財務報告と株価によると、現在の営業利益率(TTM)は 0.00% です。2026 年末時点では 0.00% でした。
Windlas Biotech Limited の営業利益率の履歴(2026 から 2026)
各年末の営業利益率
営業利益率 変化
提供された日付のデータは十分ではありません。
同業他社の営業利益率
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。